Investors and traders alike always seem to be on the lookout for new investment ideas. With the S&P 500 and the Dow Jones Industrial Average having recently hit new highs, 24/7 Wall St. decided to pour through literally hundreds of reviewed research calls to find some of the hidden gems in independent research and in Wall St. research. With analysts throwing out Buy, Sell or Hold ratings, we wanted to see which stocks have the ability to still rise by 50%, 100%, or even more.
Some of these calls are very counterintuitive and some are actually not that much more aggressive when compared to other analyst calls. Some of the other calls come with great risk and great reward possibilities if they come true. Some are value stocks and turnaround stocks, while others are simply big story growth stocks. We have shown the calls and compared them to consensus price targets from Thomson Reuters’ pool of analysts, and we also have added color on each of these calls.
Our list for April is actually 19 stocks, more than the 11 we highlighted that could rise 50% to 100% (or more) back in early March. The list for April includes the following stocks: Advanced Micro Devices Inc. (NYSE: AMD), Arch Coal Inc. (NYSE: ACI), Astex Pharmaceuticals Inc. (NASDAQ: ASTX), Bank of America Corp. (NYSE: BAC), Citigroup Inc. (NYSE: C), Bona Film Group Ltd. (NASDAQ: BONA), Gulfport Energy Corp. (NASDAQ: GPOR), Halcon Resources Corp. (NYSE: HK), MannKind Corp. (NASDAQ: MNKD), Molycorp Inc. (NYSE: MCP), OvaScience Inc. (OVSC), Peabody Energy Corp. (NYSE: BTU), Rosetta Resources Inc. (NASDAQ: ROSE), Rubicon Technology Inc. (NASDAQ: RBCN), Ruby Tuesday Inc. (NYSE: RT), Sangamo Biosciences Inc. (NASDAQ: SGMO), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Ultra Petroleum Corp. (NYSE: UPL) and Warner Chilcott PLC (NASDAQ: WCRX).
Advanced Micro Devices Inc. (NYSE: AMD) is a call from mid-March, and we might have skipped it entirely had this analyst call not been so aggressive. Wells Fargo maintained its Outperform rating on the troubled chip and processor turnaround stock. What stood out was the $5 to $7 price range offered up, implying a double and then some, compared to the $2.60 share price at the time. That leaves even more upside from the $2.30 or so share price now. We had a hard time grasping the good news that Wells Fargo saw, but the analyst team there is not exactly thought poorly of by Wall St. and Main Street.
Arch Coal Inc. (NYSE: ACI) is in the battered coal sector, but it could have a nice snapback if UBS is correct. Trading in the mid-$5 range, down from the high $70s in 2008, this down and out stock could have nice upside. The UBS target is $9, and the Wall St. consensus price target is $7.65. That is close to 80% upside projected at UBS, but even the consensus target price comes to a projected 50% upside now. Another fairly fresh call at the end of March from Jefferies was at the street-high target price of $12, which implies more than 100% upside, if its insight is accurate.
Astex Pharmaceuticals Inc. (NASDAQ: ASTX) was a fresh call from April 3, and the stock responded to the research call. RBC Capital Markets initiated coverage at Outperform with a $9.00 price target. That implied 80% upside at the time, ahead of the company discussing data on its drug pipeline at the upcoming American Association for Cancer Research annual meeting. The upside to this call is still about 61%, if the firm is correct.